For months, patients and prescribers have watched the FDA issue increasingly detailed guidance on GLP-1 receptor agonists and peptide therapies, particularly around compounded versions of retatrutide and AOD-9604. But federal guidance is not the same as federal enforcement, and many observers have noticed a widening gap between what the FDA says and what actually happens at the pharmacy counter. Now, state pharmacy boards are stepping into that gap, moving faster than the federal agency to impose their own restrictions, inspections, and disciplinary actions. This shift has real consequences for anyone relying on compounded retatrutide or AOD-9604, and understanding the new landscape is essential for making safe, informed decisions.
This article explains why state pharmacy boards are taking action, what that action looks like, how it affects access to compounded retatrutide and AOD-9604, and what patients should watch for in the coming months. We will also connect the dots to recent regulatory developments, including the FDA's evolving stance on GLP-1 quality and the divergent paths these two peptides are taking under scrutiny.
Why the FDA Guidance Left a Gap
The FDA's authority over compounded drugs is complex. Under the Federal Food, Drug, and Cosmetic Act, compounded medications are not approved by the FDA the way manufactured drugs are. Instead, they are regulated through a patchwork of provisions, including Section 503A for traditional compounding pharmacies and Section 503B for outsourcing facilities. The FDA can issue guidance documents, inspect facilities, and take enforcement action, but it does not license pharmacies or pharmacists. That power belongs to the states.
In 2025 and early 2026, the FDA released a series of guidance documents and public statements addressing GLP-1 quality concerns, particularly around semaglutide and tirzepatide compounding. Retatrutide, an investigational triple agonist not yet approved for any indication, and AOD-9604, a peptide fragment sometimes marketed for weight loss, were caught up in this broader scrutiny. The FDA made clear that it considers many compounded peptide products to be outside the scope of lawful compounding, especially when they are copies of FDA-approved drugs or when they are made from bulk substances that are not on the approved list. However, the agency stopped short of issuing a blanket ban, and enforcement actions remained sporadic.
That left a vacuum. Patients could still find compounding pharmacies willing to produce retatrutide and AOD-9604, often through telemedicine platforms with minimal oversight. State pharmacy boards, which have direct authority over pharmacy licenses and pharmacist conduct, began to see complaints, adverse event reports, and quality failures. In response, many boards have started issuing their own rules, conducting inspections, and disciplining pharmacies that compound these peptides without proper controls.
What State Pharmacy Boards Are Doing
State boards of pharmacy operate independently, so their actions vary. However, several common patterns have emerged across states that are taking a more aggressive stance on retatrutide and AOD-9604 compounding.
1. Issuing Interpretive Statements and Emergency Rules
Some boards have published formal statements clarifying that compounding retatrutide or AOD-9604 from bulk substances is not permitted under state law unless specific criteria are met. For example, a board may state that a compounded drug must be for an individually identified patient with a valid prescription, must not be a copy of a commercially available product, and must be made from an FDA-approved bulk substance or one that appears on the FDA's 503A bulks list. Since retatrutide is not FDA-approved and AOD-9604 is not on the bulks list for most uses, these statements effectively prohibit most compounding of these peptides.
2. Conducting Targeted Inspections
Boards are increasingly inspecting pharmacies that advertise retatrutide or AOD-9604 compounding services. Inspectors look at sourcing records for active pharmaceutical ingredients, sterility testing, beyond-use dating, and patient-specific documentation. Pharmacies that cannot demonstrate compliance face citations, fines, or license suspension. In some cases, boards have coordinated with the FDA to share inspection findings, leading to federal warning letters or seizures.
3. Disciplining Pharmacists and Pharmacies
Disciplinary actions have ranged from letters of admonition to full license revocation. A common violation is compounding without a valid patient-specific prescription, which occurs when pharmacies ship large quantities of retatrutide or AOD-9604 to clinics or telemedicine companies for office use. Another frequent violation is using non-pharmaceutical-grade peptides purchased from unregistered suppliers. Boards are also cracking down on misleading advertising that implies these compounded products are FDA-approved or equivalent to approved drugs.
4. Collaborating Across State Lines
Because many compounding pharmacies ship across state lines, individual state boards have limited reach. To address this, the National Association of Boards of Pharmacy (NABP) has facilitated information sharing and joint investigations. Some states have adopted reciprocity agreements that allow a board in one state to discipline a pharmacy based on findings from another state. This means a pharmacy operating in a permissive state can still face consequences if it ships to a stricter state.
Retatrutide Compounding: A Special Case
Retatrutide is an investigational drug being developed by Eli Lilly as a triple agonist targeting GLP-1, GIP, and glucagon receptors. It is not approved by the FDA for any use, and its safety and efficacy profile is still being established in clinical trials. Despite this, compounding pharmacies have been producing retatrutide for weight loss and metabolic conditions, often marketed as a "research chemical" or "not for human consumption" to evade regulatory scrutiny. This practice has drawn sharp criticism from the FDA and state boards alike.
The FDA has stated that compounding investigational drugs like retatrutide is generally not permissible because there is no FDA-approved labeling to guide compounding, and the risks are unknown. State boards have echoed this concern, noting that pharmacies compounding retatrutide cannot verify the identity, purity, or potency of the bulk peptide, and they cannot provide adequate patient counseling. As a result, many boards now treat any compounding of retatrutide as a per se violation, regardless of the prescriber's rationale.
This hardline stance is consistent with the FDA's broader GLP-1 quality guidance, which we covered in detail in our article on retatrutide compounding restrictions in 2026. That guidance emphasized that pharmacies should not compound drugs that are essentially copies of approved or investigational products, and it listed retatrutide as a high-risk substance. State boards have used that guidance as a basis for their own enforcement, even though the FDA has not yet issued a formal rule.
AOD-9604: The Regulatory Gray Zone
AOD-9604 is a modified fragment of human growth hormone (hGH) that has been studied for weight loss and cartilage repair. It is not approved by the FDA for any indication, and its status as a dietary supplement ingredient was effectively ended by the FDA's 2023 determination that it is not a lawful dietary ingredient. However, AOD-9604 remains available through compounding pharmacies and online peptide sellers, often marketed as a "research peptide" or "for laboratory use only."
State pharmacy boards have been slower to act on AOD-9604 than on retatrutide, partly because AOD-9604 is not as closely associated with the GLP-1 boom and partly because its regulatory status is murkier. Some boards have taken the position that AOD-9604 cannot be compounded because it is not a recognized bulk drug substance for compounding under Section 503A. Others have allowed compounding if the pharmacy can demonstrate a legitimate medical purpose and proper sourcing. This inconsistency has created confusion for patients and prescribers.
The FDA's recent advisory panel vote on six peptides, including AOD-9604, added another layer of uncertainty. As we discussed in our analysis of the FDA panel vote on six peptides, the panel's recommendations could lead to formal restrictions on AOD-9604 compounding, but no final rule has been issued. In the meantime, state boards are filling the void with their own interpretations, and some have begun issuing cease-and-desist letters to pharmacies that compound AOD-9604 for human use.
How Patients Are Affected
The shift toward state-level enforcement has immediate consequences for patients who have been using compounded retatrutide or AOD-9604. The most obvious effect is reduced access. Pharmacies that once shipped these peptides nationwide are now refusing orders from certain states, or they are shutting down their peptide compounding operations entirely. Telemedicine platforms that prescribed these compounds are also pulling back, citing regulatory risk.
Patients who can still obtain compounded retatrutide or AOD-9604 face higher prices and longer wait times. Some pharmacies are requiring extensive documentation, including proof of a face-to-face examination, lab work, and a detailed treatment plan. Others are limiting quantities or requiring patients to sign informed consent forms that acknowledge the experimental nature of the product. These barriers are intended to reduce liability, but they also make it harder for patients to access care.
There is also a safety dimension. State board actions are often triggered by adverse event reports or quality failures. Patients who continue to use compounded retatrutide or AOD-9604 from unregulated sources face risks of contamination, incorrect dosing, and unknown long-term effects. The FDA has repeatedly warned about these risks, and state boards are now echoing those warnings with enforcement. For a deeper look at the quality concerns, see our article on retatrutide compounding risks amid FDA GLP-1 quality concerns.
What to Watch for Next
The regulatory landscape for compounded retatrutide and AOD-9604 is likely to become even more restrictive in the coming months. Several developments are worth monitoring.
- State legislative action: Some state legislatures are considering bills that would explicitly ban the compounding of investigational peptides or require pharmacies to report all peptide compounding to the state board. These bills could pass quickly in states with strong pharmacy board influence.
- FDA enforcement escalation: The FDA has signaled that it will increase inspections of compounding pharmacies that produce GLP-1 agonists and related peptides. Warning letters and seizures are expected to rise, which will further pressure state boards to act.
- NABP model rules: The National Association of Boards of Pharmacy is developing model language for state boards to adopt regarding peptide compounding. If adopted widely, this could create a uniform national standard that is stricter than current FDA guidance.
- Litigation: Pharmacies and telemedicine companies that have built business models around compounded retatrutide and AOD-9604 are likely to challenge state board actions in court. These cases could clarify the limits of state authority and the scope of lawful compounding.
Patients and prescribers should also watch for changes in the FDA's approach to retatrutide specifically. The drug is expected to receive FDA approval for weight loss in the next few years, and once approved, compounding of retatrutide will almost certainly be prohibited as a copy of an approved drug. In the meantime, state boards are treating it as an unapproved new drug, which is a stricter standard than the FDA has formally adopted. This disconnect is a key reason why state action is outpacing federal guidance.
Practical Guidance for Patients and Prescribers
If you are currently using or considering compounded retatrutide or AOD-9604, there are steps you can take to protect yourself and stay on the right side of the law.
- Check your state board's position. Most state pharmacy boards publish guidance or FAQs on their websites. Search for "retatrutide" or "AOD-9604" on your board's site to see if any restrictions apply. If your state has banned compounding of these peptides, do not attempt to obtain them from out-of-state pharmacies, as you may be violating state law.
- Verify the pharmacy's license and reputation. Use the NABP's online verification tool to confirm that the pharmacy is licensed in your state and has no disciplinary actions. Be wary of pharmacies that market retatrutide or AOD-9604 as "research chemicals" or "not for human use" , these are red flags.
- Ask about sourcing and testing. A legitimate compounding pharmacy should be able to provide a certificate of analysis for the active ingredient, proof of sterility testing, and a beyond-use date based on stability data. If the pharmacy cannot or will not provide this information, do not use it.
- Discuss alternatives with your prescriber. There are FDA-approved GLP-1 receptor agonists, such as semaglutide and tirzepatide, that may be appropriate for your condition. While these drugs also face compounding restrictions, they have established safety profiles and
Specific outcomes referenced from studies represent observed effects in defined populations under defined conditions.